Answers are grounded in this paper and cite their sources.
Clinical trials evaluate cardiovascular safety of precision olfactory delivery dihydroergotamine in acute migraine, indicating its clinical profile.
To report the cardiovascular (CV) safety of dihydroergotamine mesylate (DHE) administered by precision olfactory delivery (INP104) from two clinical trials.
No takes yet. Share an insight, caveat, or question.
Dafer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: